Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cocrystal Pharma ( (COCP) ).
On April 30, 2026, Cocrystal Pharma announced that its first oral protease inhibitor CDI-988 for norovirus prevention and treatment was highlighted in an oral presentation at the 39th International Conference on Antiviral Research in Prague, underscoring its scientific profile in the antiviral field. The presentation detailed the drug’s novel mechanism of action targeting a highly conserved region of the norovirus 3CL protease across strains and coronaviruses, and showcased Phase 1 data supporting advancement into a human challenge study.
Following favorable safety and tolerability results from a randomized, double-blind, placebo-controlled Phase 1 trial in healthy adults, Cocrystal has moved CDI-988 into an ongoing Phase 1b human challenge study at Emory University in collaboration with the University of North Carolina. The fully enrolled Stage 1 cohort is assessing inoculum infectivity, to be followed by prevention and treatment cohorts designed to demonstrate proof-of-concept through reductions in clinical symptoms and viral shedding, a key milestone for a program that has secured FDA Fast Track designation in an area lacking approved norovirus therapies.
CDI-988, developed using Cocrystal’s proprietary structure-based platform, has shown favorable gastrointestinal-targeted pharmacokinetics and potent antiviral activity in preclinical GII.4-infected human enteronoid models, supporting its potential utility in high-risk, semi-closed settings where norovirus outbreaks are common. As norovirus continues to impose an estimated $60 billion annual economic burden globally and drives substantial morbidity and mortality, particularly among vulnerable populations and in developing nations, successful proof-of-concept for CDI-988 could materially enhance Cocrystal’s position in the antiviral market and address a significant unmet medical need.
The most recent analyst rating on (COCP) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Neutral.
The score is held down primarily by weak financial performance (no meaningful revenue, ongoing losses, and negative cash flow with equity erosion). Technicals are mixed but supported by the price trading above key moving averages, and corporate events add some upside via FDA Fast Track and clinical progress; valuation remains unfavorable due to the negative P/E and lack of dividend support.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses including SARS-CoV-2, and rhinoviruses. The company applies structure-based drug discovery technologies and Nobel Prize-winning expertise to create antiviral drug candidates for high-burden infectious diseases.
Cocrystal’s pipeline is aimed at areas with significant unmet medical need, including norovirus, a leading cause of acute gastroenteritis with substantial global economic and health impacts. By prioritizing orally available direct-acting antivirals that can be stockpiled and deployed in outbreak settings, the company is positioning itself within the broader antiviral market as a specialist in mechanism-driven, small-molecule therapies.
Average Trading Volume: 2,462,721
Technical Sentiment Signal: Sell
Current Market Cap: $19.16M
For an in-depth examination of COCP stock, go to TipRanks’ Overview page.